While we have been becoming more international and formulations-driven over the past decade, the acquisition of Taro in 2010 places us firmly on a new growth orbital, with over half our sales now coming from North America.
We are well on our way to the future, with brands registered in major branded generic markets of the world, and in most of these markets, promoted by a high quality field force.
In the high value US generics market we are working to become a trusted, high quality generic company, with a balanced portfolio comprising both of complex and simple-to-file generics including injectables, controlled substances and dermatologicals. As we build this part of our business, our insistence on technology and the cost advantage will remain unchanged. We are open to acquisitions in the US generic space.
In India, where we are built leadership in chronic therapy areas over the last 25 years, we will be working hard to retain leadership and add to prescription share.
In key international markets across Asia, South East Asia, Russia, China, the Middle East, Latam and Africa where we have a footprint firmly in place, we will continue to build prescription driven sales and customer share of mind. Backed with a strong network and established company equity, we would be an excellent partner for a company seeking to license out products across markets.
Sun Pharmaceutical Industries Ltd. - Pharmaceuticals, US Generics, API, NCE, NDDS
News Articles
Contact Us
